Introduction

Screening Mammography -State of the Art and Limitations
As has been recently confirmed by an independent review performed by the Institute of Medicine in a report entitled Saving Women's Lives, Strategies for Breast Cancer Detection and Diagnosis (1), the main tool for breast cancer screening is still screen-film mammography. There is broad consensus that it saves lives through early detection of breast cancer. It is perhaps the most completely studied screening tool for any disease, having been submitted to seven screening trials in four different countries over the past 40 years (2). There has been some controversy about its effect on breast cancer mortality, particularly for women in their 40's, with some reviewers arguing that it has no effect even for older women (3). The most recent review of the data by multiple independent organizations, including the International Agency for Research on Cancer of the World Health Organization (March 2002) (4), the Global Mammography Summit (June 2002) , and the U.S. Preventive Health Task Force (September 2002) , has led to broad agreement about the utility of this screening tool (5, 6) . Breast cancer mortality is believed to be reduced by an estimated 20 to 30% (7, 8) , and possibly as high as 50% (9, 10) due to the use of screening mammography. Any new technique must compete with these numbers in order to supplant screening with mammography. The bar has indeed been set very high.
Even though mammography saves some lives, it is by no means perfect. There are still approximately 40,000 women and 400 men who die annually of breast cancer in the United States (11). The sensitivity of screening mammography, or its ability to find cancer when it is present in the breast, is estimated to range from 83 to 95 percent (1). That means that 5-17% of women with breast cancer do not have their diagnosis made through mammography, but as a result of palpation or other tests. In addition, many breast cancers are too advanced to cure when they are detected. The sensitivity is even lower in women with radiographically dense breasts, with one author estimating it as low as 48% (12). Such dense breasts, appearing nearly radiographically opaque on mammography, tend to occur in younger women and in women on estrogen replacement therapy.
Furthermore, there are many false alarms with screening mammography. Studies estimate the specificity of screening mammography, or the ability to determine whether a woman does not have cancer when she has a negative test, at 90 to 98 percent (13). This is somewhat reassuring until one realizes just how rare cancer is in a screening (asymptomatic) population. Most women do not have cancer at the time that they present for the screening test. The rate of breast cancer in an average risk population is 5-7 per 1000 women who present for their first mammogram and 2-3 per 1000 women who present for subsequent screening mammograms (14). In the US, the rate of positive screening mammograms tends to be between 5-10%. In Europe, the rate is closer to 1%. That means 100 women in the US and 10 women in Europe are called back for additional tests for every 2 to 7 who subsequently are diagnosed with breast cancer. These false positives cost a lot of money to an already stressed health care system and lead to some patient anxiety and morbidity. In fact, two studies have suggested a woman who gets screened has a 50% chance of an abnormal examination over a 10-year period (15, 16) .
Why are there so many false positives, particularly in the US? Mammography finds three types of lesions -masses, calcifications and architectural distortions. In the US, there is a tendency, possibly partially due to patient expectations and the physician's desire to avoid litigation, to investigate all new findings, unless they are characteristically benign (for example, skin calcifications). This entails the performance of additional mammographic views and/or sonography, followed by biopsy if needed. In the US, about 1% of women who undergo screenings subsequently undergo biopsy or aspiration of a finding. The rate of positive biopsies in the US ranges from 20-40%. In Europe, it's closer to 70%. In fact, sonography and mammography in even the most capable hands are not routinely able to consistently distinguish cancer from non-cancer when a lesion is present in the breast, and the risk of missing a breast cancer is deemed sufficiently high to warrant aggressive work-up of lesions with as low as a 1% or higher rate of malignancy. There has been work on distinguishing cancer from non-cancer in evaluating masses to allow for short-term interval follow-up (watchful waiting) rather than biopsy (17, 18), but these papers have not made a significant impact on the rates of biopsies in the US. Cysts and fibroadenomas, the most common benign breast lesions, often undergo aspiration or biopsy rather than follow-up. There are no large series of clustered calcifications that have undergone follow-up rather than biopsy so most of these lesions undergo stereotactic core or open biopsy. Fortunately, large-core needle biopsy of nonpalpable lesions with sonographic or stereotactic guidance has been shown to be as accurate as open biopsy, saving the health care system millions of dollars annually and saving many American women the added morbidity of surgery (19) .
Clearly, there is room for improvement for breast cancer diagnosis, both in increasing sensitivity for women with dense breasts and in increasing specificity. The soon-to-beconcluded Digital Mammographic Imaging Screening Trial, sponsored by the American College Radiology Imaging Network (ACRIN), funded by the United States National Cancer Institute (NCI)/National Institutes of Health (NIH) will determine whether digital mammography offers such an advance over traditional screen-film mammography. That study, which enrolled 49,500 women at 34 centers in the US and Canada, provides a blueprint for the sorts of studies that will be needed to prove that a new technology can supplant screen-film mammography; its results will be available in the spring of 2005. In fact, while DMIST will show whether digital is equal, or more or less accurate than film mammography in the same women (who underwent both tests), it will not prove that the women's lives have been saved equally effectively. In the case of digital mammography, the finding of the same number or more cancers can credibly suggest that the same number or more lives will be saved. Most experts believe that any test that aspires to replace mammography must ultimately show that it can also reduce breast cancer mortality, not just find more cancers (20) . It is possible that the course of disease for the additional cancers found by a new technology is not affected by earlier diagnosis. It is possible that the earlier diagnosis leads to longer time between breast cancer diagnosis and death, but no additional length of life, a so-called "lead time bias". Ideally, for any new technology to replace mammography as a screening tool, there should be a large multicenter clinical trial that shows not only that more cancers can be found but also that breast cancer mortality in the populations screened can actually be reduced.
Furthermore, the current screening guidelines in the US are uniform across the entire population of women over 40 years old. There is some evidence that there are women at such low-risk of breast cancer by virtue of low serum estradiol that they might not need screening for breast cancer (21), presumably even if they have other known risk factors for breast cancer. Likewise, women at highrisk from breast cancer might benefit from enhanced screening imaging tools (22). Two ongoing ACRIN trials, one on breast MRI, ACRIN 6667 and one on breast US, ACRIN 6666, will assess the use of these additional tools for screening of high-risk women. Some have already demonstrated the potential of these technologies (23, 12) . Other potentially useful screening tools include genetic tests and serum proteomic markers.
More individualized screening tools and recommendations are potentially available in the next 5 years after these ACRIN trials and others are completed. Potentially useful screening tools on the horizon that might undergo future clinical trials may be breast tomography, digital subtraction mammography, and digital mammography with Computer Aided Detection (CAD).
Overtreatment of Potentially Nonlethal Malignancies
The diagnosis of ductal carcinoma in situ (DCIS) has increased approximately tenfold in the US and other developed countries since the introduction of population-based screening mammography. Many argue that some of these lesions represent cancers that would never cause a patient's death and that therefore these nonlethal cancers are being diagnosed and treated excessively, causing unneeded morbidity and mortality (24, 25) . DCIS currently represents about 14% of all new breast cancers and about 20% of screen-detected breast cancers in the US (26, 24) .
Tumors confined to the breast do not kill women. Women die only after breast cancer has invaded and spread to other organs. However, the earliest form of breast cancer, DCIS (breast cancer still confined to the duct) is a significant risk factor for the development of invasive disease and its presence may precede the development of invasive tumor. The diagnosis of DCIS does not indicate the invasive tumor will always develop (27, 28). One study showed a death rate from invasive breast cancer of only 1.9-3.4% within 10 years of the diagnosis of DCIS, with the lower mortality rate applying to those women who were diagnosed at a later time (24). These results suggest either that more nonlethal cancers are being diagnosed through screening or improved therapies have reduced mortality, or both. Autopsy studies have shown that many women dying from other (non breast cancer) causes have a high rate of incidental DCIS (29).
The current therapy for DCIS is surgery (either mastectomy or breast-conserving surgery (BCS)), often accompanied by radiotherapy (RT) and hormone therapy (tamoxifen, for those women with estrogen-receptor positive tumors or as a chemopreventative agent for the development of additional later breast cancers). More extensive surgery, even mastectomy, is deemed appropriate for cases with more extensive DCIS, which is DCIS involving larger areas of the breast. This is usually indicated by diffuse malignant-appearing calcifications at mammography. In addition, women who have persistently positive tumor margins after attempted surgery tend to undergo mastectomy (30). Localized (under 4 cm) DCIS is often treated with BCS plus RT. BCS plus RT significantly reduced the rate of recurrence of DCIS compared with BCS alone in three recent randomized trials (31), from approximately 30% without RT to 15% with it. There was no difference in mortality between the two therapies when compared to each other and when compared to mastectomy (2%). Only about half of local recurrences, that is those occurring within the breast itself, are DCIS while approximately the other half are the more dangerous form of breast cancer, invasive ductal carcinomas.
Many argue that DCIS is not overtreated (32-34). These advocates believe that the increasing incidence of DCIS simply reflects more compulsive regular screening of the population. These people believe that eventually the higher rate of DCIS will yield lower breast cancer mortality rates in the screened population. This viewpoint is supported by the higher than expected numbers of invasive breast cancers in women with DCIS than in the general population, the increased risk of DCIS and invasive breast cancer in women treated for DCIS, and genetic studies of women with DCIS and invasive breast cancer, which show the same rate of genetic abnormalities in women with both forms of breast cancer (32-34).
Ideally, clinicians would like to determine which DCIS lesions are likely to become invasive breast cancer and/or lead to the death of the patient. Perhaps there are some women who can forego therapy completely. In general, high-grade DCIS, as determined by the pathologist after the lesion is sampled with a needle or surgery, is more likely to be associated with an invasive tumor. Mammography does offer some clues to this diagnosis, but again, this is not extremely specific. Molecular imaging tests, together with serum markers, might allow clinicians to gauge the aggressiveness of mammographically-apparent lesions in vivo, perhaps precluding biopsy and ultimately therapy. One candidate tool is breast magnetic resonance spectroscopy (MRS) for choline. One can envision the creation of agents that label cell surface markers that occur specifically in aggressive malignancies to help in the solution to this problem. As an aside, this is perhaps just as urgent a problem in the area of prostate cancer diagnosis and therapy. In fact, the problem is more significant for prostate cancer therapy because of the significant concomitant post-surgical complications, incontinence and impotence. Of course, the use of any new diagnostic test must be balanced with the causation of downstream false positives and the morbidity that those cause, of course, which is why clinical trials of any new modality must be pursued so that clinicians can ascertain what tests are best suited for their individual patients and why.
Another Role for Imaging Where Improvement is Neededthe Monitoring of the Effectiveness of Therapy
Another ACRIN trial, ACRIN 6657, is currently investigating whether breast MRI can determine whether novel chemotherapeutic regimens are working well in individual patients, particularly in the treatment of advanced breast cancer (stage 3 or higher). Women with such advanced disease at the time of diagnosis are at substantial risk of death (40% or higher, 5 year mortality rates is quite typical). Clinicians want to be able to switch regimens midstream if the initial therapies are not working. Mammography is poorly suited to determine the response to therapy over time. We need tools that will allow us to determine the biological activity of tumors, not just allow us to see whether a tumor has grown or shrunk (35).
The use of breast MRI in this setting is an active area of investigation at present. Virtually all breast cancers, even those as small as a few millimeters, enhance with MRI imaging when gadolinium is administered (36). Reported sensitivities are from 95-100%, but many benign lesions also enhance (22, 37) . MRI has also shown promise as a staging tool (38).
It is possible that the sensitivity of breast MRI during chemotherapy may be reduced by chemotherapy, however (39).
Other imaging tools that might be useful in this setting are MRS, positron emission tomography with novel agents, sonography and digital mammography with intravenous contrast.
Another Potential Imaging Application -Guidance of Percutaneous Therapy of Small Breast Cancers
Interest in the percutaneous ablation of small, early breast cancers is quite high. The methods for non-surgical treatment of breast cancer that have been published in small pilot studies include radiofrequency ablation (RFA), microwave phased array thermotherapy, high-intensity focused ultrasound (HIFU), cryoablation, and laser therapy.
RFA uses high frequency alternating current introduced into a breast lesion through a 2 cm probe, placed percutaneously with ultrasound guidance. This has generally been performed in an outpatient setting under local anesthesia (40, 41) . One small study revealed good tumor killing and pathologic-imaging correlation with post-therapy MRI (42).
Microwave phased array thermotherapy uses heat delivered through a catheter introduced into the compressed breast, with the patient in a prone position, under local anesthesia. One pilot study revealed some response to this therapy with either tumor shrinkage or necrosis in most of the patients treated in this manner (43). Post-therapy imaging to predict tumor response is needed.
High intensity focused ultrasound, which is delivered to the intact breast with MRI guidance, has also shown encouraging results. One randomized study of 48 women with invasive breast cancer compared mastectomy to HIFU followed by mastectomy (44). Another study revealed a correlation between post-treatment MRI and residual tumor at core biopsy (45).
Cryoablation, or the use of cold to treat breast tumors, has been successfully applied to fibroadenomas with sonographic guidance (46), with some encouraging early and limited experience in women with invasive breast cancer (47) (48) (49) . Again, correlation with post-therapeutic imaging to predict response is needed.
Laser therapy administered stereotaxically under local anesthesia has been tested in 54 women with invasive and in situ breast cancer. Subsequent surgical excision of the residual tumor revealed a success rate for complete tumor ablation of 70% (50).
Less invasive ways than surgery for treating early and small breast cancers will be available in the near future. Imaging will be required both to administer these therapies and to manage patients afterwards. Predicting which women do and do not need surgery through post-treatment imaging will be very important in the future. This might be accomplished through MRI, or other imaging tools. Ideally, randomized clinical trials of different therapeutic regimens (for example, RFA vs. lumpectomy) will be performed before widespread adoption of these less invasive techniques.
Conclusion
Breast cancer screening with mammography and physical examination has been successfully utilized to reduce breast cancer mortality. While it is not perfect, it sets a high standard that any new modality must reach if it is to replace mammography for either screening or diagnosis. There is definitely room for improvement in both settings. In addition, there are some areas where clinicians definitely want and need new tools. These are the monitoring and administration of noninvasive therapies and the improved determination of whether cancers are potentially lethal without the use of a tissue diagnosis.
